Logo image of ZVSA

ZYVERSA THERAPEUTICS INC (ZVSA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ZVSA - US98987D3008 - Common Stock

0.3113 USD
-0.24 (-43.3%)
Last: 7/16/2025, 8:00:02 PM
0.289 USD
-0.02 (-7.16%)
After Hours: 7/16/2025, 8:00:02 PM
Fundamental Rating

1

ZVSA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. While ZVSA seems to be doing ok healthwise, there are quite some concerns on its profitability. ZVSA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ZVSA had negative earnings in the past year.
In the past year ZVSA has reported a negative cash flow from operations.
In the past 5 years ZVSA always reported negative net income.
In the past 5 years ZVSA always reported negative operating cash flow.
ZVSA Yearly Net Income VS EBIT VS OCF VS FCFZVSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

ZVSA has a Return On Assets (-42.14%) which is in line with its industry peers.
ZVSA has a Return On Equity (-108.77%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -42.14%
ROE -108.77%
ROIC N/A
ROA(3y)-182.17%
ROA(5y)-622.67%
ROE(3y)-364.67%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZVSA Yearly ROA, ROE, ROICZVSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ZVSA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZVSA Yearly Profit, Operating, Gross MarginsZVSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for ZVSA has been increased compared to 1 year ago.
ZVSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ZVSA Yearly Shares OutstandingZVSA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
ZVSA Yearly Total Debt VS Total AssetsZVSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

ZVSA has an Altman-Z score of -9.49. This is a bad value and indicates that ZVSA is not financially healthy and even has some risk of bankruptcy.
ZVSA has a Altman-Z score of -9.49. This is in the lower half of the industry: ZVSA underperforms 72.12% of its industry peers.
ZVSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.49
ROIC/WACCN/A
WACCN/A
ZVSA Yearly LT Debt VS Equity VS FCFZVSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

2.3 Liquidity

ZVSA has a Current Ratio of 0.18. This is a bad value and indicates that ZVSA is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of ZVSA (0.18) is worse than 95.86% of its industry peers.
A Quick Ratio of 0.18 indicates that ZVSA may have some problems paying its short term obligations.
ZVSA has a Quick ratio of 0.18. This is amonst the worse of the industry: ZVSA underperforms 95.68% of its industry peers.
Industry RankSector Rank
Current Ratio 0.18
Quick Ratio 0.18
ZVSA Yearly Current Assets VS Current LiabilitesZVSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 99.60% over the past year.
EPS 1Y (TTM)99.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -21.81% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y93%
EPS Next 2Y33.34%
EPS Next 3Y-38.29%
EPS Next 5Y-21.81%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZVSA Yearly Revenue VS EstimatesZVSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 20M 40M 60M 80M
ZVSA Yearly EPS VS EstimatesZVSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ZVSA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZVSA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZVSA Price Earnings VS Forward Price EarningsZVSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZVSA Per share dataZVSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

ZVSA's earnings are expected to decrease with -38.29% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.34%
EPS Next 3Y-38.29%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZVSA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZYVERSA THERAPEUTICS INC

NASDAQ:ZVSA (7/16/2025, 8:00:02 PM)

After market: 0.289 -0.02 (-7.16%)

0.3113

-0.24 (-43.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12
Earnings (Next)08-07 2025-08-07
Inst Owners7.44%
Inst Owner Change-99.99%
Ins Owners0.04%
Ins Owner Change0%
Market Cap1.52M
Revenue(TTM)N/A
Net Income(TTM)-8.84M
Analysts82.5
Price Target122.4 (39218.98%)
Short Float %4.14%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.19
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.18
EYN/A
EPS(NY)-3.98
Fwd EYN/A
FCF(TTM)-1.14
FCFYN/A
OCF(TTM)-1.14
OCFYN/A
SpS0
BVpS1.67
TBVpS-2.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.14%
ROE -108.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-182.17%
ROA(5y)-622.67%
ROE(3y)-364.67%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.18
Quick Ratio 0.18
Altman-Z -9.49
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.96%
EPS Next Y93%
EPS Next 2Y33.34%
EPS Next 3Y-38.29%
EPS Next 5Y-21.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.98%
OCF growth 3YN/A
OCF growth 5YN/A

ZYVERSA THERAPEUTICS INC / ZVSA FAQ

Can you provide the ChartMill fundamental rating for ZYVERSA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to ZVSA.


What is the valuation status of ZYVERSA THERAPEUTICS INC (ZVSA) stock?

ChartMill assigns a valuation rating of 0 / 10 to ZYVERSA THERAPEUTICS INC (ZVSA). This can be considered as Overvalued.


What is the profitability of ZVSA stock?

ZYVERSA THERAPEUTICS INC (ZVSA) has a profitability rating of 1 / 10.


How financially healthy is ZYVERSA THERAPEUTICS INC?

The financial health rating of ZYVERSA THERAPEUTICS INC (ZVSA) is 4 / 10.